HRP20161545T1 - Supstituirani derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova - Google Patents

Supstituirani derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova Download PDF

Info

Publication number
HRP20161545T1
HRP20161545T1 HRP20161545TT HRP20161545T HRP20161545T1 HR P20161545 T1 HRP20161545 T1 HR P20161545T1 HR P20161545T T HRP20161545T T HR P20161545TT HR P20161545 T HRP20161545 T HR P20161545T HR P20161545 T1 HRP20161545 T1 HR P20161545T1
Authority
HR
Croatia
Prior art keywords
phenyl
methoxy
carbonyl
amino
pyridine
Prior art date
Application number
HRP20161545TT
Other languages
English (en)
Inventor
Sven Ruf
Thorsten Sadowski
Klaus Wirth
Herman Schreuder
Christian Buning
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44041622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161545(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20161545T1 publication Critical patent/HRP20161545T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)

Claims (12)

1. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, [image] naznačen time da A je odabran iz niza koji sadrži C(R1) i N; D je odabran iz niza koji sadrži C(R2) i N; E je odabran iz niza koji sadrži C(R3); L je odabran iz niza koji sadrži C(R4) i N; gdje barem jedan i najviše dva od A, D ili L je N; G je odabran iz niza koji sadrži R71-O-C(O)-, R72-N(R73)-C(O)- i tetrazol-5-il; R1 je odabran iz niza koji sadrži vodik, halogen, (C1-C6)-alkil, HO-, (C1-C6)-alkil-O-, (C1-C6)-alkil-S(O)m- i NC-; R2 je odabran iz niza koji sadrži vodik, halogen, (C1-C7)-alkil, (C1-C6)-alkil-O-, (C1-C6)-alkil-CO-, (C1-C6)-alkil-CO-HN-, -NR12R13, Het2, (C3-C7)-cikloalkil-CsH2s- i Ar-CsH2s-, pri čemu s je cijeli broj izabran iz niza koji sadrži 0, 1, 2 i 3; R3 je R11-O-; R4 je odabran iz niza koji sadrži vodik, halogen, (C1-C6)-alkil, (C1-C6)-alkil-O-, HO-, NR12R13, Het2; R10 je odabran iz niza koji sadrži vodik, halogen, (C1-C6)-alkil, (C1-C6)-alkil-O-, (C1-C6)-alkil-S(O)m-, HO-, -NR12R13, Het2, fenil-CsH2s-(O)t-, pri čemu s je cijeli broj izabran iz niza koji sadrži 0, 1, 2 i 3, te pri čemu t je cijeli broj izabran iz niza koji sadrži 0 i 1; uz uvjet da jedan od R1, R2, R3, R4 ili R10 je ciklički supstituent; R11 je odabran iz niza koji sadrži vodik i (C1-C10)-alkil; R12 i R13 su međusobno neovisno izabrani iz niza koji sadrži vodik i R15; R15 je (C1-C6)-alkil koji je proizvoljno supstituiran s jednim ili više istih ili različitih supstituenata odabranih iz niza koji čine halogen, HO- i (C1-C6)-alkil-O-; R30 je odabran iz niza koji sadrži R31, (C3-C7)-cikloalkil, R32-CuH2u- i Het3-CuH2u-, pri čemu u je cijeli broj izabran iz niza koji sadrži 0, 1, 2 i 3; R31 je (C1-C10)-alkil koji je proizvoljno supstituiran s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C3-C7)-cikloalkil, HO-, (C1-C6)-alkil-O-, (C1-C6)-alkil-S(O)m- i NC-; R32 je odabran iz niza koji sadrži fenil i aromatski 5-člani ili 6-člani monociklički heterocikl koji sadrži jedan, dva ili tri jednaka ili različita heteroatoma u prstenu odabrana iz niza koji sadrži dušik, kisik i sumpor i vezan je preko atoma ugljika u prstenu, pri čemu su fenil i heterocikl svi proizvoljno supstituirani s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, R33, HO-, (C1-C6)-alkil-O-, R33-O-, R33-(C1-C4)-alkil-O-, -O-CH2-O-, -O-CF2-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, (C1-C4)-alkil-NH-S(O)2-, di((C1-C4)-alkil)N-S(O)2-, H2N-, (C1-C6)-alkil-NH-, di((C1-C6)-alkil)N-, Het1, (C1-C4)-alkil-C(O)-NH-, Ar-C(O)-NH-, (C1-C4)-alkil-S(O)2-NH- i NC-; R33 je odabran iz niza koji sadrži fenil i aromatski 5-člani ili 6-člani monociklički heterocikl koji sadrži jedan, dva ili tri jednaka ili različita heteroatoma u prstenu odabrana iz niza koji sadrži dušik, kisik i sumpor i vezan je preko atoma ugljika u prstenu, pri čemu su fenil i heterocikl svi proizvoljno supstituirani s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, HO-, (C1-C6)-alkil-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, (C1-C4)-alkil-NH-S(O)2-, di((C1-C4)-alkil)N-S(O)2- i NC-; R40 je odabran iz niza koji sadrži vodik i (C1-C4)-alkil; ili R30 i R40 zajedno su (CH2)x koji je proizvoljno supstituiran s jednim ili više istih ili različitih (C1-C4)-alkil supstituenata, pri čemu x je cijeli broj izabran iz niza koji sadrži 2, 3, 4 i 5; R50 je vodik; R60 je vodik; R71 je odabran iz niza koji sadrži vodik i (C1-C8)-alkil koji je proizvoljno supstituiran s jednim ili više istih ili različitih supstituenata odabranih iz niza koji čine (C1-C6)-alkil-O- i (C1-C6)-alkil-C(O)-O-; R72 i R73 su međusobno neovisno izabrani iz niza koji sadrži vodik i (C1-C2)-alkil -; Ar, neovisno jedna od druge skupine Ar, je odabrana iz niza koji sadrži fenil i aromatski 6-člani monociklički heterocikl koji sadrži jedan, dva ili tri jednaka ili različita heteroatoma u prstenu odabrana iz niza koji sadrži dušik, kisik i sumpor i vezana je preko atoma ugljika u prstenu, pri čemu su fenil i heterocikl svi proizvoljno supstituirani s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, HO-(C1-C6)-alkil, Het4, -(CH2)x-fenil, (C1-C6)-alkil-O-, (C3-C7)-cikloalkil-(CH2)x-O-, -CF3, -CO-(C1-C6)-alkil, -NR12R13, Het2, -CO-NR12R13, CO-Het2, (C1-C6)-alkil-S(O)m-, H2N-S(O)2- i NC-; i pri čemu fenil može biti supstituiran s -CH=CH-CH=CH-, -O-CH2-O-, -O-CH2-CH2-O-, -O-CF2-O- ili -N((C1-C3)-alkil)-CH=CH-; Het1, neovisno jedna od druge skupine Het1, je zasićeni ili nezasićeni 4-člani do 8-člani monociklički heterocikl koji sadrži dušikov atom prstena preko kojeg je Het1 vezan i proizvoljno jedan ili dva ista ili različita dodatna heteroatoma u prstenu odabrana iz niza koji čine dušik, kisik i sumpor, koji je proizvoljno supstituiran s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C4)-alkil, HO-, (C1-C4)-alkil-O-, okso i NC-; Het2 je zasićeni 4-člani do 7-člani monociklički heterocikl koji sadrži dušikov atom prstena preko kojeg je Het2 vezan i proizvoljno jedan dodatni heteroatom u prstenu odabran iz niza koji čine dušik, kisik i sumpor, koji je proizvoljno supstituiran s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C4)-alkil, HO- i (C1-C4)-alkil-O-; Het3, neovisno jedna od druge skupine Het3, je zasićeni 4-člani do 7-člani monociklički heterocikl koji sadrži jedan ili dva ista ili različita heteroatoma u prstenu odabrana iz niza koji čine dušik, kisik i sumpor i vezan je preko atoma ugljika u prstenu, koji je proizvoljno supstituiran s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine fluor, (C1-C4)-alkil i okso; m, međusobno neovisno je broj m, koji je cijeli broj izabran iz niza koji sadrži 0, 1 i 2; pri čemu sve cikloalkilne skupine, međusobno neovisno, su proizvoljno supstituirane s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine fluor i (C1-C4)-alkil; pri čemu sve skupine alkil, CsH2s, CuH2u i (CH2)x, međusobno neovisno, i neovisno od bilo kojih drugih supstituenata, su proizvoljno supstituirane s jednim ili više fluorovih supstituenata.
2. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, kako je zatraženo u zahtjevu 1, naznačen time da G je odabran iz niza koji sadrži R71-O-C(O)- i R72-N(R73)-C(O)-; R30 je R32-CuH2u-, pri čemu u je cijeli broj izabran iz niza koji sadrži 0 i 1; R32 je odabran iz niza koji sadrži fenil i aromatski 6-člani monociklički heterocikl koji sadrži jedan ili dva dušikova atoma kao heteroatome prstena, pri čemu su fenil i heterocikl svi proizvoljno supstituirani s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, R33, HO-, (C1-C6)-alkil-O-, R33-O-, R33-(C1-C4)-alkil-O-, -O-CH2-O-, -O-CF2-O-, (C1-C6)-alkil-S(O)m-, di((C1-C4)-alkil)N-S(O)2-, H2N-, di((C1-C6)-alkil)N-, Het1, (C1-C4)-alkil-C(O)-NH-, Ar-C(O)-NH- i NC-; R33 je odabran iz niza koji sadrži fenil i aromatski 6-člani monociklički heterocikl koji sadrži jedan ili dva dušikova atoma kao heteroatome prstena, pri čemu su fenil i heterocikl svi proizvoljno supstituirani s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, HO-, (C1-C6)-alkil-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, di((C1-C4)-alkil)N-S(O)2- i NC-; R40 je vodik.
3. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više od zahtjeva 1 i 2, naznačen time da G je R71-O-C(O)-; R30 je R32 -CuH2u-, pri čemu u je 0; R32 je odabran iz niza koji sadrži fenil, pri čemu je fenil proizvoljno supstituiran s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, R33, HO-, (C1-C6)-alkil-O-, R33-O-, R33-(C1-C4)-alkil-O-, -O-CH2-O-, -O-CF2-O-, (C1-C6)-alkil-S(O)m-, di((C1-C4)-alkil)N-S(O)2-, H2N-, di((C1-C6)-alkil)N-, Het1, (C1-C4)-alkil-C(O)-NH-, Ar-C(O)-NH-i NC-; R33 je odabran iz niza koji sadrži fenil, pri čemu je fenil proizvoljno supstituiran s jednim ili više jednakih ili različitih supstituenta odabranih iz niza koji čine halogen, (C1-C6)-alkil, (C3-C7)-cikloalkil, HO-, (C1-C6)-alkil-O-, (C1-C6)-alkil-S(O)m-, H2N-S(O)2-, di((C1-C4)-alkil)N-S(O)2- i NC-; R40 je vodik.
4. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više od zahtjeva 1 do 3, naznačen time da formula I je odabrana iz niza podformula I-1, I-2, I-4 i I-6 [image] [image] [image]
5. Spoj s formulom I-1, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, kako je zatraženo u zahtjevu 4, naznačen time da [image] R2 je Ar-CsH2s-, pri čemu s je cijeli broj izabran iz niza koji sadrži 0; R3 je odabran iz niza koji sadrži vodik, halogen, R11-O-, HO-, (C1-C6)-alkil i (C1-C6)-alkil-O-; poželjno HO- i (C1-C6)-alkil R4 je vodik; R10 je vodik.
6. Spoj s formulom I, u bilo kojem od njegovih stereoizomernih oblika ili smjesa stereoizomernih oblika u bilo kojem omjeru, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više od zahtjeva 4 do 5, naznačen time da R3 je -O-CH3.
7. Spoj s formulom I, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više od zahtjeva 1 do 6, naznačen time da se bira od: (S)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-3-o-tolil-propanske kiseline (S)-3-(2,4-diklor-fenil)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-{[6-(2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-3-p-tolil-propanske kiseline (S)-3-[(5-metoksi-6-o-tolil-piridin-2-karbonil)-amino]-3-p-tolil-propanske kiseline (S)-3-{[5-metoksi-6-(2-trifluormetil-fenil)-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(3-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[5-metoksi-6-(2-metoksi-fenil)-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2,4-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2,3-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2-klor-5-trifluormetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(3-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2-klor-5-trifluormetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2,3-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2,5-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2,5-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(3,5-dimetil-izoksazol-4-il)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(4-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2,3-dimetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(5-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(4-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(5-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(2-fluor-5-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(3-klor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(3-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(5-klor-2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-(2-fluor-fenil)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-{[6-(2,4-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-(2-fluor-fenil)-3-[(5-metoksi-6-o-tolil-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-(2-fluor-fenil)-3-{[5-metoksi-6-(2-trifluormetil-fenil)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-fluor-fenil)-3-{[5-metoksi-6-(2-metoksi-fenil)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(2-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-(2-fluor-fenil)-3-{[6-(2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(2,4-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2,3-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2,3-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2,5-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(4-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(3,5-dimetil-izoksazol-4-il)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2,3-dimetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(5-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(4-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(5-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(2-fluor-5-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(3-klor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(5-klor-2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-{[6-(3-klor-2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-(2-fluor-fenil)-3-{[5-metoksi-6-(2-metil-furan-3-il)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(2-klor-3-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-fluor-fenil)-propanske kiseline (S)-3-(2-klor-fenil)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,4-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(4-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[5-metoksi-6-(3-trifluormetil-fenil)-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(2,4-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-[(5-metoksi-6-p-tolil-piridin-2-karbonil)-amino]-3-o-tolil-propanske kiseline (S)-3-{[6-(3-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[5-metoksi-6-(2-metoksi-fenil)-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-[(5-metoksi-6-m-tolil-piridin-2-karbonil)-amino]-3-o-tolil-propanske kiseline (S)-3-{[6-(2-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(3,4-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(2,5-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(2,5-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(3,5-dimetil-izoksazol-4-il)-5-metoksi-piridin-2-karbonil]-amino}-3-O-tolil-propanske kiseline (S)-3-{[6-(2,3-dimetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(2,4-dimetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-O-tolil-propanske kiseline (S)-3-{[6-(2-klor-5-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-O-tolil-propanske kiseline (S)-3-(2-klor-fenil)-3-[(6-metoksi-5-o-tolil-piridin-3-karbonil)-amino]-propanske kiseline (S)-3-(2-klor-fenil)-3-{[5-metoksi-6-(2-metoksi-fenil)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-[(5-metoksi-6-m-tolil-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,4-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,3-diklor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,3-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,5-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(4-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,3-dimetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(5-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(4-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(4-klor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(5-fluor-2-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2-fluor-5-trifluormetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[5-metoksi-6-(2-trifluormetil-fenil)-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(2,4-difluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-cijano-2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-O-tolil-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2-fluor-5-metoksi-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2-fluor-5-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(3-klor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(3-fluor-2-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(5-klor-2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline (S)-3-(2-klor-fenil)-3-[(5-metoksi-6-pirazin-2-il-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-{[6-(3-klor-2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline (S)-3-(2-klor-fenil)-3-{[5-metoksi-6-(2-metil-furan-3-il)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-{[6-(2-klor-3-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline (S)-3-{[6-(2-klor-3-metil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline.
8. Spoj s formulom I, ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih, prema bilo kojem ili više od zahtjeva 1 do 6, naznačen time da se bira od (S)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-3-o-tolil-propanske kiseline (S)-3-(2,4-diklor-fenil)-3-[(5-metoksi-6-fenil-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-[(5-fenil-piridin-2-karbonil)-amino]-3-o-tolil-propanske kiseline (S)-3-(2-klor-fenil)-3-[(5-metoksi-6-naftalen-2-il-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-(2-klor-fenil)-3-[(5-metoksi-6-pirazin-2-il-piridin-2-karbonil)-amino]-propanske kiseline (S)-3-(2-klor-fenil)-3-[(6-metoksi-5-naftalen-2-il-piridin-3-karbonil)-amino]-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2,3-dimetil-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-klor-fenil)-3-{[6-(2-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-fluor-fenil)-3-{[5-metoksi-6-(1,3,5-trimetil-1H-pirazol-4-il)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-(2-fluor-fenil)-3-{[5-metoksi-6-(1-metil-1H-indol-5-il)-piridin-2-karbonil]-amino}-propanske kiseline (S)-3-[(5-metoksi-6-m-tolil-piridin-2-karbonil)-amino]-3-o-tolil-propanske kiseline (S)-3-{[6-(2-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(3,5-dimetil-izoksazol-4-il)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline (S)-3-{[6-(4-klor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-p-tolil-propanske kiseline (S)-3-{[6-(5-Acetil-tiofen-2-il)-5-metoksi-piridin-2-karbonil]-amino}-3-(2-klor-fenil)-propanske kiseline (S)-3-{[6-(2-fluor-fenil)-5-metoksi-piridin-2-karbonil]-amino}-3-o-tolil-propanske kiseline.
9. Postupak za dobivanje spoja s formulom I ili njegove fiziološki prihvatljive soli ili fiziološki prihvatljivog solvata bilo kojeg od njih prema bilo kojem ili više od zahtjeva 1 do 8, koji sadrži reakciju spoja s formulom II sa spojem s formulom III, [image] naznačen time da skupine A, D, E, L, G, R10, R30, R40, R50 i R60 u spojevima s formulama II i III su definirane kao u spojevima formule I, te dodatne funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorskih skupina, i skupina J u spoju s formulom II je HO-, (C1-C4)-alkil-O- ili halogen.
10. Spoj s formulom I prema bilo kojem ili više od zahtjeva 1 do 8 ili njegova fiziološki prihvatljiva sol ili fiziološki prihvatljiv solvat bilo kojeg od njih naznačen time da je za uporabu kao farmaceutski proizvod.
11. Farmaceutski pripravak, naznačen time da sadrži barem jedan spoj s formulom I prema bilo kojem ili više od zahtjeva 1 do 8 ili njegova fiziološki prihvatljiva sol ili fiziološki prihvatljiv solvat bilo kojeg od njih i farmaceutski prihvatljiv nosač.
12. Uporaba spoja s formulom I prema bilo kojem ili više od zahtjeva 1 do 8 ili njegove fiziološki prihvatljive soli ili fiziološki prihvatljivog solvata bilo kojeg od njih naznačena time da je za proizvodnju lijeka za liječenje zatajenja srca, kongestivnog zatajenja srca, kardiomiopatije, infarkta miokarda, lijeve ventrikularne disfunkcije, srčane hipertrofije, valvularnih bolesti srca, hipertenzije, ateroskleroze, periferne arterijske okluzivne bolesti, restenoze, poremećaja vaskularne propusnosti, liječenje edema, tromboze, reumatoidnog artritisa, osteoartritisa, zatajenja bubrega, cistične fibroze, kroničnog bronhitisa, kronične opstruktivne plućne bolesti, astme, imunoloških bolesti, komplikacija povezanih s dijabetesom, fibroznih bolesti, boli, ishemije ili reperfuzijskog oštećenja ili neurodegenerativnih bolesti, ili za kardioprotekciju ili renoprotekciju ili kao diuretik (sa samostalno liječenje ili u kombinaciji s utvrđenim diureticima).
HRP20161545TT 2011-01-26 2016-11-21 Supstituirani derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova HRP20161545T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305078 2011-01-26
EP12701126.0A EP2667870B1 (en) 2011-01-26 2012-01-26 Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
PCT/EP2012/051189 WO2012101197A1 (en) 2011-01-26 2012-01-26 Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
HRP20161545T1 true HRP20161545T1 (hr) 2016-12-30

Family

ID=44041622

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161545TT HRP20161545T1 (hr) 2011-01-26 2016-11-21 Supstituirani derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova

Country Status (29)

Country Link
US (3) US8669370B2 (hr)
EP (1) EP2667870B1 (hr)
JP (1) JP5957467B2 (hr)
KR (1) KR20140007399A (hr)
CN (1) CN103442712B (hr)
AR (1) AR085013A1 (hr)
AU (1) AU2012210513B2 (hr)
BR (1) BR112013016508A2 (hr)
CA (1) CA2822120C (hr)
CL (1) CL2013002129A1 (hr)
CO (1) CO6761373A2 (hr)
CY (1) CY1118844T1 (hr)
DK (1) DK2667870T3 (hr)
ES (1) ES2604556T3 (hr)
HK (1) HK1187253A1 (hr)
HR (1) HRP20161545T1 (hr)
HU (1) HUE029781T2 (hr)
IL (3) IL227025A (hr)
LT (1) LT2667870T (hr)
MA (1) MA34917B1 (hr)
MX (3) MX347157B (hr)
PL (1) PL2667870T3 (hr)
PT (1) PT2667870T (hr)
RU (1) RU2632897C2 (hr)
SG (2) SG10201600592WA (hr)
SI (1) SI2667870T1 (hr)
UY (1) UY33874A (hr)
WO (1) WO2012101197A1 (hr)
ZA (1) ZA201304463B (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33874A (es) 2011-01-26 2012-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
JP5959075B2 (ja) * 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
PT2928881T (pt) * 2012-12-07 2018-05-07 Hoffmann La Roche Novos derivados de piridina
AR095764A1 (es) 2013-03-28 2015-11-11 Sanofi Sa Derivados de ácido biaril-propiónico y su uso como productos farmacéuticos
AU2014243070B2 (en) 2013-03-28 2017-12-21 Sanofi Biaryl-propionic acid derivatives and their use as pharmaceuticals
MY182908A (en) * 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
CN115093400B (zh) * 2021-09-18 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂及其用途和制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (es) 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampicilina
TW406076B (en) * 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
WO2003003008A1 (en) * 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
JP2004203871A (ja) * 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
BR0317659A (pt) 2002-12-23 2005-12-06 Aventis Pharma Gmbh Derivados de pirazol como inibidores de fator xa
JP2005145839A (ja) * 2003-11-12 2005-06-09 Japan Science & Technology Agency 新規なカテプシンａ阻害剤
WO2006076202A1 (en) 2005-01-10 2006-07-20 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
AR058051A1 (es) 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
US7511063B2 (en) 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
TWI405571B (zh) 2006-12-29 2013-08-21 Abbott Gmbh & Co Kg 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
JP5504171B2 (ja) 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP2011524894A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
EP2391624B1 (en) 2009-01-30 2013-01-16 Boehringer Ingelheim International GmbH Azaquinazolinediones useful as chymase inhibitors
MX2011012628A (es) * 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
UY33874A (es) 2011-01-26 2012-08-31 Sanofi Aventis Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas

Also Published As

Publication number Publication date
JP2014505063A (ja) 2014-02-27
ZA201304463B (en) 2014-02-26
CA2822120C (en) 2019-02-26
CY1118844T1 (el) 2018-01-10
DK2667870T3 (en) 2016-12-12
PT2667870T (pt) 2016-11-16
IL249826A0 (en) 2017-02-28
AR085013A1 (es) 2013-08-07
HK1187253A1 (zh) 2014-04-04
HUE029781T2 (en) 2017-04-28
IL227025A (en) 2017-05-29
RU2632897C2 (ru) 2017-10-11
AU2012210513A1 (en) 2013-08-15
MX347157B (es) 2017-04-18
BR112013016508A2 (pt) 2016-09-27
CN103442712A (zh) 2013-12-11
EP2667870A1 (en) 2013-12-04
US20120252809A1 (en) 2012-10-04
PL2667870T3 (pl) 2017-02-28
NZ613672A (en) 2015-04-24
LT2667870T (lt) 2016-12-12
CA2822120A1 (en) 2012-08-02
CN103442712B (zh) 2016-01-20
WO2012101197A1 (en) 2012-08-02
UY33874A (es) 2012-08-31
ES2604556T3 (es) 2017-03-07
IL249825A0 (en) 2017-02-28
US8669370B2 (en) 2014-03-11
SI2667870T1 (sl) 2016-12-30
AU2012210513B2 (en) 2016-09-22
US9029559B2 (en) 2015-05-12
US20140194445A1 (en) 2014-07-10
US9120783B2 (en) 2015-09-01
US20140135328A1 (en) 2014-05-15
EP2667870B1 (en) 2016-08-24
SG191826A1 (en) 2013-08-30
MX340370B (es) 2016-07-07
JP5957467B2 (ja) 2016-07-27
MA34917B1 (fr) 2014-02-01
RU2013139349A (ru) 2015-03-10
CO6761373A2 (es) 2013-09-30
MX2013007608A (es) 2013-09-06
SG10201600592WA (en) 2016-02-26
KR20140007399A (ko) 2014-01-17
CL2013002129A1 (es) 2013-12-20

Similar Documents

Publication Publication Date Title
HRP20161545T1 (hr) Supstituirani derivati 3-heteroaroilamino-propionske kiseline i njihova upotreba kao lijekova
HRP20150075T1 (hr) Kisikom supstituirani derivati 3-heteroarilaminopropionske kiseline i njihova upotreba kao farmaceutska sredstva
ES2787704T3 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis B
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
WO2019008506A1 (en) N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
ES2909486T3 (es) Sistemas de administración para liberación controlada de fármaco
JP2016505586A5 (hr)
WO2020012339A1 (en) Chemical compounds
CN104350049B (zh) 作为激酶抑制剂的取代氨基喹唑啉
CN108601952B (zh) 雷公藤内酯的葡萄糖缀合物、类似物及其用途
ES2911040T3 (es) Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2)
MX2010010619A (es) Moduladores de quimioquina.
US11136325B2 (en) Pyrrolopyrimidine and pyrrolopyridine derivatives
WO2020031107A1 (en) Chemical compounds
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
WO2013054351A1 (en) Heterocyclic compounds
CN102649795B (zh) 10-甲氧基喜树碱衍生物、制备方法和用途
US20190314360A1 (en) Antitumor agent and bromodomain inhibitor
ES2911183T3 (es) Compuesto para inhibir selectivamente quinasas y uso del mismo
CA2907668A1 (en) Trail enhancers for the selective killing of cancer cells
ES2954148T3 (es) Ciertos inhibidores de proteína cinasa
CA3063804A1 (en) A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof
AU2019214193B2 (en) Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
Nair et al. IV. Discovery of CXCR3 antagonists substituted with heterocycles as amide surrogates: Improved PK, hERG and metabolic profiles
CN102250190B (zh) 一种齐墩果酸皂苷类衍生物、其盐的制备方法及其用途